[
  {
    "ts": null,
    "headline": "GEHC vs. PODD: Which Stock Is the Better Value Option?",
    "summary": "GEHC vs. PODD: Which Stock Is the Better Value Option?",
    "url": "https://finnhub.io/api/news?id=b5b75395f81025514f0b461f038ffccb9fe1dcda7c05370e998cd140f2cc2272",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1735663212,
      "headline": "GEHC vs. PODD: Which Stock Is the Better Value Option?",
      "id": 132218005,
      "image": "https://media.zenfs.com/en/zacks.com/b369e357aa3d42cc28ac674490d4ae83",
      "related": "PODD",
      "source": "Yahoo",
      "summary": "GEHC vs. PODD: Which Stock Is the Better Value Option?",
      "url": "https://finnhub.io/api/news?id=b5b75395f81025514f0b461f038ffccb9fe1dcda7c05370e998cd140f2cc2272"
    }
  },
  {
    "ts": null,
    "headline": "Insulet price target raised to $300 from $270 at BTIG",
    "summary": "BTIG raised the firm’s price target on Insulet (PODD) to $300 from $270 and keeps a Buy rating on the shares as part of a broader research note updating the firm’s models in select Medical Technology names. BTIG is increasing its estimates for U.S. Omnipod sales in the second half of FY25 to reflect the anticipated tailwind of accelerated adoption that it sees happening as Insulet expands its marketing into the T2D – type 2 diabetes – patient population, the analyst tells investors in a research",
    "url": "https://finnhub.io/api/news?id=b3c2a25f74b5fdddde1db22c56760a428e1d7138844c5f23b1050f60e4586a90",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1735647315,
      "headline": "Insulet price target raised to $300 from $270 at BTIG",
      "id": 132218007,
      "image": "https://media.zenfs.com/en/tipranks_452/38a68defd725ddd544390055e985cfb8",
      "related": "PODD",
      "source": "Yahoo",
      "summary": "BTIG raised the firm’s price target on Insulet (PODD) to $300 from $270 and keeps a Buy rating on the shares as part of a broader research note updating the firm’s models in select Medical Technology names. BTIG is increasing its estimates for U.S. Omnipod sales in the second half of FY25 to reflect the anticipated tailwind of accelerated adoption that it sees happening as Insulet expands its marketing into the T2D – type 2 diabetes – patient population, the analyst tells investors in a research",
      "url": "https://finnhub.io/api/news?id=b3c2a25f74b5fdddde1db22c56760a428e1d7138844c5f23b1050f60e4586a90"
    }
  }
]